Loading
A phase 3 trial of Technetium-99m tilmanocept in Head and neck squamous cell carcinoma, run by Navidea Biopharmaceuticals, recorded as terminated on the registry.
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT00911326 by Navidea Biopharmaceuticals, with 101 participants recorded, started 2009-05 and due to reach its primary completion in 2013-08. Interventions recorded: Lymphoseek. Conditions recorded: Head and Neck Squamous Cell Carcinoma (HNSCC).
Linked to the drug Technetium-99m tilmanocept because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
101 enrolled.
95% CI 0.06 to 13.49; Figures from the ClinicalTrials.gov results section (first posted 2014-08-08), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| False Negative Rate (FNR)primary | Intent-to-treat (ITT) | 83 | 2.56% | - | - | link |
Shares Navidea Biopharmaceuticals, Technetium-99m tilmanocept and the tag pipeline.
Shares Navidea Biopharmaceuticals, Technetium-99m tilmanocept and the tag pipeline.
Shares Technetium-99m tilmanocept, Oral cavity cancer (mouth and tongue) and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue) and the tag pipeline.